Ren Danfeng, Cao Wenya, Liu Xiaojing, Han Qunying, Fan Wanhu, Li Guoliang, Xia Han, Zhang Xi
Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Dialysis Department of Nephrology Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Front Med (Lausanne). 2021 Nov 17;8:766400. doi: 10.3389/fmed.2021.766400. eCollection 2021.
No consensus has been reached regarding the optimal therapy for visceral leishmaniasis (VL), which affects ~12 million people worldwide. This report described four cases of VL encountered in the First Affiliated Hospital of Xi'an Jiaotong University between October 2019 and December 2020. Of the four patients, one patient experienced relapse after antimonial treatment, and the remaining patients had primary VL (including one patient with impaired kidney function and one patient with hemophagocytic syndrome). All patients received a novel treatment protocol, namely the low-dose L-AmB therapy, which was characterized by a low initial dose, cautious dose escalation, and low-dose therapy as maintenance. All patients were cured without severe complications, and there was no further recurrence during follow-up. This case series demonstrated the safety and efficacy of the low-dose L-AmB therapy for VL patients, providing novel treatment protocol for the VL.
关于内脏利什曼病（VL）的最佳治疗方法尚未达成共识，该病在全球约有1200万人受到影响。本报告描述了2019年10月至2020年12月期间在西安交通大学第一附属医院遇到的4例VL病例。在这4例患者中，1例患者在接受锑剂治疗后复发，其余患者为初发VL（包括1例肾功能受损患者和1例噬血细胞综合征患者）。所有患者均接受了一种新的治疗方案，即低剂量两性霉素B脂质体（L-AmB）疗法，其特点是初始剂量低、谨慎增加剂量以及低剂量维持治疗。所有患者均治愈且无严重并发症，随访期间无进一步复发。该病例系列证明了低剂量L-AmB疗法对VL患者的安全性和有效性，为VL提供了新的治疗方案。
